Clinical Trials Logo

Safety Issues clinical trials

View clinical trials related to Safety Issues.

Filter by:

NCT ID: NCT04491266 Completed - Safety Issues Clinical Trials

Tolerability and Modulatory Action of the Butyrate Releaser N-(1-carbamoyl-2-phenyl-ethyl) Butyramide

Start date: January 9, 2012
Phase: N/A
Study type: Interventional

Accumulating evidence is showing that gut microbiota could play a key role in gastrointestinal tract and immune system development and function. Many beneficial effects elicited by gut microbiota are mediated its metabolites. Short chain fatty acids (SCFAs) are major metabolites produced by gut microbiota. Among SCFA, butyrate has emerged as pivotal regulator of many gastrointestinal function and immune system development and function. Butyrate is produced by intestinal microbial fermentation of resistant starches and dietary fiber. It regulates several beneficial intestinal and extra-intestinal functions, among the first it serves as the primary energy source for the gut epithelium, increases mineral absorption, stimulates proliferation and differentiation of normal colon epithelial cells, improves the gut barrier function by stimulation of the formation of mucin, antimicrobial peptides, and tight-junction proteins, interacts with the immune system and has anti-inflammatory effects. Butyrate also seems to regulate the expression of antimicrobial peptides in particular upregulating transcription of cathelicidin thanks to his action of histone deacetylase inhibitor and it has been shown to induce human β-defensin 2 (HBD-2) mRNA expression in colonocytes, although there are few publications reporting its regulation of defensins (Berni Canani R et al. W J Gastroenterol. 2011;17(12):1519). Preliminary data showed that breast milk contains butyrate. Butyrate could be an ideal compound for infant formulas for an efficient regulation of a number of protective actions at gastrointestinal tract level and at systemic level. A new butyrate releaser, useful for all the known applications of butyrate, presenting physiochemical characteristics suitable for easy oral administration (free from unpleasant organoleptic properties of butyrate): N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed. The molecule is a butyrate amide with the amino acid phenylalanine, solid, odourless, tasteless, stable at gastric pH, and able to release butyrate constantly throughout gastrointestinal tract. The aim of the study was to evaluate tolerability and safety profile of a nutritional intervention with FBA in formula fed at term neonates. The effects on the expression of innate immunity biomarkers as well as on neonatal gut function were also assessed.

NCT ID: NCT04485481 Completed - Safety Issues Clinical Trials

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

Start date: September 8, 2020
Phase: Phase 1
Study type: Interventional

A two (2) part study to evaluate the safety, tolerability and PK of ADX-914

NCT ID: NCT04403334 Completed - Safety Issues Clinical Trials

Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin

Start date: January 2, 2018
Phase: Phase 4
Study type: Interventional

Comparative safety study of intracameral levofloxacin versus moxifloxacin for postoperative infection prophylaxis

NCT ID: NCT04365608 Completed - Influenza Clinical Trials

Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment

Start date: March 20, 2020
Phase: N/A
Study type: Interventional

The safety and efficacy of a laryngoscopy as a primary intubation tool in urgent endotracheal intubation of cardiac arrest patients with suspected/confirmed COVID-19 has not been well-described in the literature. This study will answer whether using a Vie Scope laryngoscope will impact on the efficacy and safety of intubation compared with a traditional direct laryngoscopy.

NCT ID: NCT04335045 Completed - Safety Issues Clinical Trials

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

Start date: September 25, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study was to determine the safety and tolerability of PH100, a purified phlorotannins from a brown alga Ecklonia cava and the pharmacokinetics of its major compounds 8,8'-bieckol, dieckol, and phlorofucofuroeckol A (PFF-A), after single, ascending, oral doses of PH100 Capsules (over-encapsulated tablets) in healthy adult volunteers.

NCT ID: NCT04311476 Completed - Safety Issues Clinical Trials

Autologous Cord Blood Cells for Prevention of BPD in Preterm

Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

To study the effect of Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates

NCT ID: NCT04301895 Completed - Acute Pain Clinical Trials

Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression

Start date: April 30, 2019
Phase: Phase 1
Study type: Interventional

Volunteers will receive a weight-based opioid (remifentanil) infusion for 10 minutes. In the first run, serial pupillary measurements (pupillary unrest, pupil diameter) will be taken at baseline, and at 2.5-minute intervals during the infusion and a 25-minute recovery period afterwards. After a washout period, the experiment will be repeated in each subject (second run). The two runs differ only by presence versus absence of verbal interaction.

NCT ID: NCT04226482 Completed - Safety Issues Clinical Trials

Review of Efficacy of Used ultraSonic Energy Device

REUSED
Start date: May 27, 2019
Phase: N/A
Study type: Interventional

Single-use medical instruments are intended by the manufacturers for single-use only or for single-patient-use only. Nevertheless, single-use instruments are being reused more than once in many countries around the world. The reasons are mainly economic in developing countries and environmental in developed countries. Concerns are being raised regarding reused instruments sterility and efficacy. Since there is paucity of evidence on safety of multiple use of single-use instruments in surgery, we decided to conduct a clinical study comparing the same surgical procedure performed with new versus reused surgical instrument. We decided to study laparoscopic appendectomy which is a simple and the most common emergency surgery. Instrument under the scrutiny is ultrasonic scalpel which uses high-frequency ultrasound vibration for coagulating and cutting tissue. In the studied period of time, all eligible patients with acute appendicitis will be randomized in two groups, first having surgery with new device and the second having surgery with reused device. Removed appendix will be analyzed for lateral thermal damage and the patients will be followed-up for one month for potential differences in clinical outcomes like pain-killers consumption, length of stay and postoperative complications.

NCT ID: NCT04207710 Completed - Pain Clinical Trials

Safety of Gebauer's Pain Ease and Gebauer's Ethyl Chloride

Start date: January 26, 2021
Phase: Phase 4
Study type: Interventional

This study aims to determine if Gebauer's Pain Ease or Gebauer's Ethyl Chloride topical anesthetic sprays are safe for use as numbing agents prior to placing epidurals and arterial lines, based on whether they introduce increased microbial growth after application to skin. Due to the recent national shortage of lidocaine, we hope to find a suitable alternative to lidocaine for topical analgesia when placing arterial lines and epidurals. Our hypothesis is that the sprays will not affect the sterility of the area. We will compare microbial growth from three subsequent swabs taken from a single area of skin on the wrist and lower back: one with no treatment, the second after treatment with ChloraPrep, and the third after applying one of the numbing sprays. If there is significantly higher growth in the swabs containing the topical anesthetic spray versus the ChloraPrep alone, this will indicate that the sprays introduce microbes to the sites of skin.

NCT ID: NCT04196335 Completed - Safety Issues Clinical Trials

I Can sEe Left Atrial Appendage (ICELAA) Clinical Study

ICELAA
Start date: July 29, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess the efficacy and safety of using intra-procedural intracardiac echocardiography (ICE) for WATCHMAN FLX Device implants in subjects with non-valvular atrial fibrillation to reduce the risk of stroke.